ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2025
Efficacy of rituximab in secondary progressive multiple sclerosis: Insights from magnetic resonance imaging and disability assessments.
Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although there are a few options for the treatment of patients with secondary progressive multiple sclerosis (SPMS), rituximab (RTX) is used as an off-label treatment. This study aimed to investigate the efficacy of RTX on disability status and volumetric magnetic resonance imaging (MRI) findings in SPMS. Materials and Methods: This study was conducted on 31 patients with SPMS treated with RTX 1000 mg intravenously every 6 months. Expanded Disability Status Scale (EDSS), 25-Foot Walk Test (25-FWT), 9-Hole Peg Test (9-HPT), and brain MRI were performed at the baseline and after 12 months. Results: No significant changes were observed in EDSS, timed 25-FWT, and 9-HPT within 12 months of RTX treatment ( Conclusion: Our results showed that the level of disability based on EDSS, timed 25-FWT, and 9-HPT did not increase significantly during 12 months of treatment with RTX. These findings suggest that RTX may play a role in disease stabilization and preventing disability progression, especially in the upper limbs. Further studies with larger sample sizes are necessary to confirm this finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.